Arrhythmic Risk Stratification of Carriers of Filamin C Truncating Variants
Authors: Marta Gigli, Davide Stolfo, Giulia Barbati, Sharon Graw, Suet Nee Chen, Marco Merlo, Kristen Medo, Caterina Gregorio, Matteo Dal Ferro, Alessia Paldino, Maria Perotto, J. Peter van Tintelen, Anneline S. J. M. Te Riele, Annette F. Baas, Arthur M. Wilde, Ahmad S. Amin, Arjan C. Houweling, Perry Elliott, Douglas Cannie, Michelle Michels, Stephan A. C. Schoonvelde, Sanjay Prasad, Paz Upasana Tayal, Momina Yazdani, Deborah Morris-Rosendahl, Pablo Garcia-Pavia, Eva Cabrera-Romero, Barbara Bauce, Kalliopi Pilichou, Diane Fatkin, Renee Johnson, Daniel P. Judge, Kimberly L. Foil, Stephane Heymans, Job A. J. Verdonschot, Sophie L.V. M. Stroeks, Neal K. Lakdawala, Purohit Anisha, Matthew O’Neill, M. Benjamin Shoemaker, Dan M. Roden, Hugh Calkins, Cynthia A. James, Brittney Murray, Victoria N. Parikh, Euan A. Ashley, Chloe Reuter, Massimo Imazio, Marco Canepa, Pietro Ameri, Jiangping Song, Gianfranco Sinagra, Matthew R. G. Taylor, Luisa Mestroni
Journal: JAMA Cardiology (2025)

Importance Filamin C truncating variants (FLNCtv) are a rare cause of cardiomyopathy with heterogeneous phenotypic presentations. Despite a high incidence of life-threatening ventricular arrhythmias and sudden cardiac death (SCD), reliable risk predictors to stratify carriers of FLNCtv are lacking. Objective To determine factors predictive of SCD/major ventricular arrhythmias (MVA) in carriers of FLNCtv. Design, Setting, and Participants This was an international, multicenter, retrospective cohort study conducted from February 2023 to June 2024. The Filamin C Registry Consortium included 19 referral centers for genetic cardiomyopathies worldwide. Participants included carriers of pathogenic or likely pathogenic FLNCtv. Phenotype negative was defined as the absence of any pathological findings detected by 12-lead electrocardiogram (ECG), Holter ECG monitoring, echocardiography, or cardiac magnetic resonance. Exposures Composite of SCD and MVA in carriers of FLNCtv. Main Outcomes and Measures The primary outcome was a composite of SCD and MVA, the last including aborted SCD, sustained ventricular tachycardia, and appropriate implantable cardioverter-defibrillator (ICD) interventions. Results Among 308 individuals (median [IQR] age, 45 [33-56] years; 160 male [52%]) with FLNCtv, 112 (36%) were probands, and 72 (23%) were phenotype negative. Median (IQR) left ventricular ejection fraction (LVEF) was 51% (38%-59%); 89 participants (34%) had LVEF less than 45%, and 50 (20%) had right ventricular dysfunction. During a median (IQR) follow-up of 34 (8-63) months, 57 individuals (19%) experienced SCD/MVA, with an annual incidence rate of 4 cases per 100 person-years (95% CI, 3-6). Incidence rates were higher in probands vs nonprobands and in phenotype-positive vs phenotype-negative individuals. A predictive model estimating SCD/MVA risk was derived from multivariable analysis, which included older age, male sex, previous syncope, nonsustained ventricular tachycardia, and LVEF with a time-dependent area under the curve (AUC) ranging between 0.76 (95% CI, 0.67-0.86) at 12 months and 0.78 (95% CI, 0.70-0.86) at 72 months. Notably, the association of LVEF with the SCD/MVA risk was not linear, showing significant lower risk for values of LVEF greater than 58%, and no increase for values less than 58%. Internal validation with bootstrapping confirmed good accuracy and calibration of the model. Results were consistent in subgroups analysis (ie, phenotype-positive carriers and phenotype-positive carriers without MVA at onset). Conclusions and Relevance Results suggest that the risk of SCD/MVA in phenotype-positive carriers of FLNCtv was high. A 5-variable predictive model derived from this cohort allows risk estimation and could support clinicians in the shared decision for prophylactic ICD implantation. External cohort validation is warranted.